Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis

2017119 citationsJournal Articlegold Open Access

Authors

Alexandre Sepriano · Leiden University Medical Center

Andrea Regel · Rheumazentrum Ruhrgebiet

Désirée van der Heijde · Leiden University Medical Center

Jürgen Braun · Rheumazentrum Ruhrgebiet

Xenofon Baraliakos · Rheumazentrum Ruhrgebiet

Robert Landewé · Zuyderland Medisch Centrum

Filip Van den Bosch

Abstract

New evidence supports the efficacy and safety of TNFi both in r-axSpA and nr-axSpA. Secukinumab is the first drug targeting the IL-17 pathway in r-axSpA that has shown efficacy.

Topics & Keywords

Spondyloarthritis Studies and Treatments Rheumatoid Arthritis Research and Therapies Psoriasis: Treatment and Pathogenesis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: RMD Open

Volume 3, Issue 1, pp. e000396-e000396

DOI: 10.1136/rmdopen-2016-000396

Field-Weighted Citation Impact: 14.14